Premier Inc. Statement on FDA Announcement to Expedite Generic Drug Applications Last Updated: July 12, 2017
Filed under:
Print Friendly, PDF & Email

By Blair Childs, Senior Vice President of Public Affairs, Premier

The Premier Inc. healthcare alliance strongly supports the FDA Commissioner Gottlieb’s announcement to expedite the review of generic drug applications when there are fewer than three manufacturers in the market for a given drug product. Hospitals, caregivers and consumers have experienced significant price spikes and shortages in generic drugs when there is a lack of competition in the market. This important action will help address this problem.

We also applaud the agency’s publication of a list of the off-patent and off-exclusivity branded drugs without generic competition. After reviewing the list, Premier has already identified a number of critical drugs for patient care and already begun outreach to manufacturers to participate in the FDA’s new expedited review process.

While we applaud these important actions by the FDA to address issues that are helping to cause high drug prices and shortages, we recognize that more needs to be done. Premier recently released nine policy recommendations Congress and the administration should take to create healthier and more competitive pharmaceutical markets, and drive toward the goal of achieving a high-quality, cost-effective pharmaceutical industry.

— Blair Childs, senior vice president of public affairs, Premier